OABIW — OmniAb, Inc.

Summary of OmniAb, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by increased milestone revenue.
• Full Year 2025 Revenue: $18.7 million, compared to $26.4 million in 2024, driven by decreased license and milestone revenues.
• Net Loss: Q4 net loss was $14.2 million ($0.11 per share), slightly higher than a net loss of $13.1 million ($0.12 per share) in Q4 2024. Full year net loss was $64.8 million ($0.57 per share), compared to $62 million ($0.61 per share) in 2024.
• Operating Expenses: Decreased to $24.1 million in Q4 2025 from $26.7 million in Q4 2024; full year operating expenses were $87.6 million, down from $100.9 million in 2024.
• Cash Position: Ended 2025 with $54 million in cash and equivalents, expected to decline to $30-$35 million by the end of 2026.

2. Strategic Updates and Business Highlights

• Partner Growth: 107 partners with 407 active programs, marking a significant increase in both metrics. New license agreements were signed with notable institutions and companies.
• Technology Innovations: Launched OmniUltra, a transgenic chicken platform for antibody development, and xPloration, a high-throughput screening platform, both expected to drive future growth and attract new partners.
• Program Advancements: 25 programs advanced through development stages in 2025, including 4 moving to Phase I clinical trials, with one program reaching registration.
• Market Engagement: The company reported strong engagement from existing and new partners, particularly for its new technologies.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $25 million and $30 million, indicating a recovery from 2025 levels.
• Operating Expenses: Projected to be between $80 million and $85 million, with cash operating expenses expected to be $50 million to $55 million.
• Long-Term Outlook: Aiming for a transition from milestone-driven to more royalty-driven revenue, with over $3 billion in contracted milestones and an average royalty rate of 3.4%.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant drop in both quarterly and annual revenues compared to previous years, raising concerns about the sustainability of revenue streams.
• Net Losses: Continued net losses, although slightly improved per share, indicate ongoing financial challenges.
• Market Conditions: Potential impacts from broader market fundraising activities and economic conditions affecting partner spending and program initiation.

5. Notable Q&A Insights

• xPloration Demand: Strong interest from high-tier partners, with two systems deployed in 2025. Growth expected in 2026, though longer sales cycles are anticipated.
• Program Growth: Management expressed confidence in maintaining momentum for new program additions, driven by recent technology launches.
• Cash Flow Breakeven: While not providing a specific timeline, management indicated a trajectory towards cash flow positivity, contingent on partner program advancements.
• Royalty Structures: Most agreements involve flat royalties, with some tiered structures. The potential for higher royalties exists with newer technologies, but negotiations will influence outcomes.

Overall, while OmniAb demonstrated strong partner engagement and innovation, it faces challenges with declining revenues and ongoing net losses. The company is optimistic about future growth driven by new technologies and a recovering market.